Whitehawk Therapeutics (NASDAQ: WHWK) revenue
Whitehawk Therapeutics reported revenue of $7.1m for fiscal 2025, 72.5% less than in fiscal 2024 ($26.0m). Since fiscal 2018 its revenue has fallen by 64.6%, an average decline of 13.8% a year.
Whitehawk Therapeutics's best year of the last 8 was fiscal 2024. The biggest drop was in fiscal 2025, −72.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $7.1m | −72.5% | −$114.4m | −1,601.1% |
| 2024 | $26.0m | +6.7% | −$67.5m | −259.6% |
| 2023 | $24.4m | +60.1% | −$71.9m | −295.4% |
| 2022 | $15.2m | +8.7% | −$62.7m | −411.9% |
| 2021 | $14.0m | 0.0% | −$111.2m | −794.4% |
| 2020 | $14.0m | — | −$2.5m | −18.2% |
| 2019 | $0.0m | −100.0% | −$24.4m | — |
| 2018 | $20.2m | — | −$11.2m | −55.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Whitehawk Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Whitehawk Therapeutics ranks 377th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Whitehawk Therapeutics, −72.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 375th | Xenon Pharmaceuticals | $7.5m | — |
| 376th | Ovid Therapeutics | $7.3m | 1,181.3% |
| 377th | Whitehawk Therapeutics | $7.1m | −72.5% |
| 378th | Immunome | $6.9m | −23.2% |
| 379th | Korro Bio | $6.4m | 181.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Whitehawk Therapeutics
- How much revenue did Whitehawk Therapeutics make in fiscal 2025?
- Whitehawk Therapeutics reported revenue of $7.1m for fiscal 2025, compared with $26.0m in fiscal 2024.
- How much has the revenue of Whitehawk Therapeutics fallen?
- Between fiscal 2018 and fiscal 2025 it went from $20.2m to $7.1m: 64.6% less, an average decline of 13.8% a year.
- What was the best year for revenue at Whitehawk Therapeutics?
- Of its last 8 fiscal years, fiscal 2024, with $26.0m.
- Where does Whitehawk Therapeutics rank in its sector by revenue?
- It ranks 377th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Whitehawk Therapeutics come from?
- From the annual report (Form 10-K) that Whitehawk Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Whitehawk Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Whitehawk Therapeutics: the Whitehawk Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.